NCT03210545View on ClinicalTrials.gov

A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT)

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

November 9, 2021

Study Completion Date

February 16, 2022

Conditions
Addison Disease
Interventions
DRUG

Betamethasone

A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid betamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.

Trial Locations (1)

413 45

Centrum for Endocrinology and Metabolism, Sahlgenska University Hospital, Gothenburg

All Listed Sponsors
lead

Göteborg University

OTHER

NCT03210545 - A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT) | Biotech Hunter | Biotech Hunter